The tumor‐vascularization axis has been targeted with the application of the VEGF‐A inhibitor bevacizumab, leading to prolonged PFS (potentially also due to antiedematous effects) but not OS, both in newly diagnosed and progressive GBM [34, 42, 127, 154]. This evidence concerns the gene VEGFA and glioblastoma.